|Bid||13.10 x 800|
|Ask||17.00 x 1200|
|Day's range||12.94 - 13.75|
|52-week range||12.21 - 22.22|
|Beta (5Y monthly)||0.92|
|PE ratio (TTM)||N/A|
|Earnings date||22 Feb 2022 - 28 Feb 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||25.43|
The FDA bestows an Orphan Drug designation to Coherus (CHRS) and partner Junshi's toripalimab for the treatment of esophageal cancer.
Image source: The Motley Fool. Coherus BioSciences, inc (NASDAQ: CHRS)Q3 2021 Earnings CallNov 8, 2021, 5:00 p.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorGood day, and thank you for standing by.
Coherus BioSciences (CHRS) delivered earnings and revenue surprises of -22.50% and -5.13%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?